Subject(s)
Cholesterol/metabolism , Cysts/metabolism , Hand Dermatoses/metabolism , Adult , Crystallization , Fingers , Humans , MaleABSTRACT
The influence of tenoxicam on renal function was studied prospectively in two different populations. Group I (n = 10) was classified as "high renal risk" patients and received 20 mg of tenoxicam per day for five days. Glomerular filtration rate measured with Cr51 EDTA decreased significantly by 13 +/- 3.6% (p less than 0.01). Group II (n = 56) were outpatients from the rheumatology clinic and received 20 mg tenoxicam per day for one to five years. Plasma creatinine did not change significantly, except in one patient who had some degree of renal impairment before therapy. Tenoxicam carries no greater renal risks than other non-steroidal antiinflammatory drugs when administered to a non-"high renal risk" population. On the other hand, simple renal function monitoring should be carried out in high risk patients.